source
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
- Bristol Myers reports Phase 3 data showing mezigdomide extends survival in relapsed multiple myelomaBristol Myers Squibb presented Phase 3 results for its experimental multiple myeloma drug mezigdomide at the American Society of Clinical Oncology meeting. The study evaluated mezigdomide combined…